Luca Issi
Stock Analyst at RBC Capital
(3.76)
# 740
Out of 5,149 analysts
220
Total ratings
49.64%
Success rate
8.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Sector Perform | $9 → $15 | $13.70 | +9.49% | 8 | Mar 3, 2026 | |
| ASND Ascendis Pharma | Maintains: Outperform | $250 → $275 | $235.96 | +16.55% | 5 | Mar 3, 2026 | |
| ARGX argenx SE | Maintains: Outperform | $925 → $890 | $747.55 | +19.06% | 4 | Feb 27, 2026 | |
| BEAM Beam Therapeutics | Maintains: Sector Perform | $22 → $26 | $27.79 | -6.44% | 8 | Feb 25, 2026 | |
| MRNA Moderna | Maintains: Sector Perform | $25 → $30 | $56.18 | -46.60% | 19 | Feb 17, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $500 → $465 | $323.68 | +43.66% | 29 | Jan 20, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $82 → $95 | $78.30 | +21.33% | 11 | Dec 17, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Outperform | $52 → $80 | $64.09 | +24.82% | 11 | Dec 11, 2025 | |
| WVE Wave Life Sciences | Upgrades: Outperform | $9 → $27 | $13.62 | +98.24% | 6 | Dec 9, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Sector Perform | $7 → $10 | $8.16 | +22.55% | 3 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $57 → $28 | $28.96 | -3.31% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $85 → $8 | $11.26 | -28.95% | 8 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $42 → $50 | $59.95 | -16.60% | 15 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $19 | $9.23 | +105.85% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $30 | $15.06 | +99.20% | 4 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $45 | $9.11 | +393.96% | 7 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $2.57 | +289.11% | 9 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $18 | $19.84 | -9.27% | 7 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $7.39 | +170.64% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $2 | $0.40 | +404.80% | 6 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $10.81 | +57.26% | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $13 | $7.66 | +69.71% | 6 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $9.06 | +286.31% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $60.16 | +16.36% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $48.06 | +18.60% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $2.23 | +79.37% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $21.65 | +255.66% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $1.79 | +682.12% | 5 | Aug 7, 2024 |
Intellia Therapeutics
Mar 3, 2026
Maintains: Sector Perform
Price Target: $9 → $15
Current: $13.70
Upside: +9.49%
Ascendis Pharma
Mar 3, 2026
Maintains: Outperform
Price Target: $250 → $275
Current: $235.96
Upside: +16.55%
argenx SE
Feb 27, 2026
Maintains: Outperform
Price Target: $925 → $890
Current: $747.55
Upside: +19.06%
Beam Therapeutics
Feb 25, 2026
Maintains: Sector Perform
Price Target: $22 → $26
Current: $27.79
Upside: -6.44%
Moderna
Feb 17, 2026
Maintains: Sector Perform
Price Target: $25 → $30
Current: $56.18
Upside: -46.60%
Alnylam Pharmaceuticals
Jan 20, 2026
Maintains: Outperform
Price Target: $500 → $465
Current: $323.68
Upside: +43.66%
Ionis Pharmaceuticals
Dec 17, 2025
Maintains: Outperform
Price Target: $82 → $95
Current: $78.30
Upside: +21.33%
Arrowhead Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $52 → $80
Current: $64.09
Upside: +24.82%
Wave Life Sciences
Dec 9, 2025
Upgrades: Outperform
Price Target: $9 → $27
Current: $13.62
Upside: +98.24%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Sector Perform
Price Target: $7 → $10
Current: $8.16
Upside: +22.55%
Nov 20, 2025
Downgrades: Sector Perform
Price Target: $57 → $28
Current: $28.96
Upside: -3.31%
Nov 13, 2025
Downgrades: Sector Perform
Price Target: $85 → $8
Current: $11.26
Upside: -28.95%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $42 → $50
Current: $59.95
Upside: -16.60%
Nov 7, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $9.23
Upside: +105.85%
Nov 6, 2025
Maintains: Outperform
Price Target: $23 → $30
Current: $15.06
Upside: +99.20%
Nov 4, 2025
Maintains: Outperform
Price Target: $65 → $45
Current: $9.11
Upside: +393.96%
May 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $2.57
Upside: +289.11%
May 8, 2025
Maintains: Sector Perform
Price Target: $21 → $18
Current: $19.84
Upside: -9.27%
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $7.39
Upside: +170.64%
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.40
Upside: +404.80%
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $10.81
Upside: +57.26%
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $7.66
Upside: +69.71%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $9.06
Upside: +286.31%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $60.16
Upside: +16.36%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $48.06
Upside: +18.60%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $2.23
Upside: +79.37%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $21.65
Upside: +255.66%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $1.79
Upside: +682.12%